CN107108672B - 稠合的五环咪唑衍生物 - Google Patents

稠合的五环咪唑衍生物 Download PDF

Info

Publication number
CN107108672B
CN107108672B CN201580053711.8A CN201580053711A CN107108672B CN 107108672 B CN107108672 B CN 107108672B CN 201580053711 A CN201580053711 A CN 201580053711A CN 107108672 B CN107108672 B CN 107108672B
Authority
CN
China
Prior art keywords
alkyl
group
formula
radical
represents hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580053711.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107108672A (zh
Inventor
T·德哈罗加西亚
M·德利尼
J·P·希尔
J·R·昆西
宣梦阳
朱昭宁
D·C·布鲁金斯
M·D·卡尔米亚诺
Y·埃夫拉尔
M·C·哈钦斯
J·A·约翰逊
S·雅多
J·凯阿尔特斯
M·麦科斯
M·D·塞尔比
M·A·肖
D·L·L·斯温嫩
L·斯基奥
Y·福里谢
B·菲洛什-罗梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Match Norfin Inc
UCB SA
Original Assignee
Match Norfin Inc
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Match Norfin Inc, UCB SA filed Critical Match Norfin Inc
Publication of CN107108672A publication Critical patent/CN107108672A/zh
Application granted granted Critical
Publication of CN107108672B publication Critical patent/CN107108672B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580053711.8A 2014-10-03 2015-10-02 稠合的五环咪唑衍生物 Active CN107108672B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP14290299.8 2014-10-03
EP14290299 2014-10-03
EP15162641 2015-04-07
EP15162641.3 2015-04-07
EP15171036 2015-06-08
EP15171036.5 2015-06-08
PCT/EP2015/072868 WO2016050975A1 (en) 2014-10-03 2015-10-02 Fused pentacyclic imidazole derivatives

Publications (2)

Publication Number Publication Date
CN107108672A CN107108672A (zh) 2017-08-29
CN107108672B true CN107108672B (zh) 2019-11-08

Family

ID=54238452

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580053711.8A Active CN107108672B (zh) 2014-10-03 2015-10-02 稠合的五环咪唑衍生物

Country Status (36)

Country Link
US (3) US10202405B2 (https=)
EP (1) EP3201196B1 (https=)
JP (1) JP6629847B2 (https=)
KR (1) KR102442235B1 (https=)
CN (1) CN107108672B (https=)
AP (1) AP2017009809A0 (https=)
AU (1) AU2015326798B2 (https=)
BR (1) BR112017006669B1 (https=)
CA (1) CA2962826C (https=)
CL (1) CL2017000787A1 (https=)
CO (1) CO2017003331A2 (https=)
CR (1) CR20170167A (https=)
DK (1) DK3201196T3 (https=)
EA (1) EA032839B1 (https=)
EC (1) ECSP17027306A (https=)
ES (1) ES2885432T3 (https=)
GT (1) GT201700044A (https=)
HR (1) HRP20211605T1 (https=)
HU (1) HUE056133T2 (https=)
IL (1) IL251147B (https=)
LT (1) LT3201196T (https=)
MA (1) MA40770B1 (https=)
MX (1) MX380578B (https=)
MY (1) MY181019A (https=)
PE (1) PE20170693A1 (https=)
PH (1) PH12017500414B1 (https=)
PL (1) PL3201196T3 (https=)
RS (1) RS62423B1 (https=)
SG (1) SG11201701796XA (https=)
SI (1) SI3201196T1 (https=)
TN (1) TN2017000083A1 (https=)
TW (1) TWI719949B (https=)
UA (1) UA120764C2 (https=)
UY (1) UY36341A (https=)
WO (1) WO2016050975A1 (https=)
ZA (1) ZA201701946B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX380578B (es) * 2014-10-03 2025-03-12 Ucb Biopharma Sprl Derivados de imidazol pentaciclicos fusionados.
EP3288939A1 (en) 2015-04-17 2018-03-07 AbbVie Inc. Tricyclic modulators of tnf signaling
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
EA201892153A1 (ru) * 2016-04-01 2019-04-30 Юсб Байофарма Спрл Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf
JP6968090B2 (ja) * 2016-04-01 2021-11-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
EP3436458B1 (en) 2016-04-01 2021-06-02 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
US10766906B2 (en) 2016-04-01 2020-09-08 UCB Biopharma SRL Fused hexacyclic imidazole derivatives as modulators of TNF activity
GB201620948D0 (en) 2016-12-09 2017-01-25 Ucb Biopharma Sprl Therapeutic agents
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
CN110461842A (zh) * 2017-03-15 2019-11-15 Ucb生物制药私人有限公司 作为tnf活性调节剂的稠合五环咪唑衍生物
AU2018259040B2 (en) * 2017-04-25 2022-04-28 Sanofi Fused pentacyclic imidazole derivatives as modulators of TNF activity
MX2020010433A (es) * 2018-04-04 2020-10-28 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.
CA3117344A1 (en) 2018-10-24 2020-04-30 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
CN113683505A (zh) * 2021-09-29 2021-11-23 厦门大华本安化工安全研究院有限公司 一种含氧代环丁基的羧酸酯类化合物的制备方法
CN120418259A (zh) * 2022-11-23 2025-08-01 弗沃德医疗公司 TNFα活性的调节剂
WO2024129763A1 (en) * 2022-12-13 2024-06-20 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
WO2024148191A1 (en) * 2023-01-05 2024-07-11 Forward Therapeutics, Inc. MODULATORS OF TNF-α ACTIVITY
TW202508596A (zh) 2023-04-26 2025-03-01 法商賽諾菲公司 使用腫瘤壞死因子α之小分子抑制劑治療乾癬
WO2024251282A1 (zh) * 2023-06-09 2024-12-12 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
TW202521544A (zh) * 2023-08-16 2025-06-01 美商雷瑟拉股份有限公司 TNFα活性調節劑及其用途
WO2025068505A1 (en) 2023-09-29 2025-04-03 Sanofi Preparation of bridged pentacyclic imidazole derivatives as modulators of tnf activity, intermeditates and their preparation
WO2025137267A1 (en) * 2023-12-21 2025-06-26 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
TW202602881A (zh) * 2024-03-27 2026-01-16 大陸商海思科醫藥集團股份有限公司 雜環衍生物及其在醫藥上的應用
WO2025212627A1 (en) * 2024-04-03 2025-10-09 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025218735A1 (zh) * 2024-04-17 2025-10-23 上海翰森生物医药科技有限公司 五环类衍生物抑制剂、其制备方法和应用
WO2025240514A1 (en) * 2024-05-15 2025-11-20 Forward Therapeutics, Inc. Treatment of autoimmune or inflammatory disease
WO2025244936A1 (en) * 2024-05-20 2025-11-27 Forward Therapeutics, Inc. Modulators of tnf-alpha activity
WO2025247401A1 (zh) * 2024-05-31 2025-12-04 海思科医药集团股份有限公司 一种稠合杂环衍生物及其在医药上的应用
WO2025255096A1 (en) * 2024-06-03 2025-12-11 Dana-Farber Cancer Institute, Inc. Cycloalkyl and heterocyclic modulators of tnf activity
WO2025252251A1 (zh) * 2024-06-07 2025-12-11 上海翰森生物医药科技有限公司 含氧杂环类衍生物抑制剂、其制备方法和应用
WO2026022134A1 (en) 2024-07-23 2026-01-29 Sanofi Novel aminocarbonylation processes
WO2026021586A1 (zh) * 2024-07-26 2026-01-29 上海瀚辰星泰医药科技有限公司 一种多环化合物及其制备方法和应用
WO2026027449A1 (en) 2024-07-29 2026-02-05 Sanofi Fused pentacyclic imidazole derivatives
WO2026051930A1 (zh) * 2024-09-04 2026-03-12 苏州湃玥生物科技有限公司 一种作为tnf活性调节剂的稠合五环苯并咪唑衍生物及其制备方法和应用
WO2026055519A1 (en) 2024-09-06 2026-03-12 Rapt Therapeutics, Inc. Fused ring imidazole compounds
WO2026068677A1 (en) * 2024-09-27 2026-04-02 Sanofi Processes for the preparation of fused pentacyclic imidazoles and intermediates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013186229A1 (en) * 2012-06-11 2013-12-19 Ucb Pharma S.A. Tnf -alpha modulating benzimidazoles
WO2014009295A1 (en) * 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity
WO2014009296A1 (en) * 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyrazine derivatives as modulators of tnf activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0449649A3 (en) 1990-03-30 1992-09-02 Arizona Board Of Regents, Arizona State University Antineoplastic quinones and methods of using same
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
BRPI0408477A (pt) 2003-03-10 2006-04-04 Pfizer compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
TW201242953A (en) 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
CN103702994B (zh) 2011-06-20 2016-03-23 沃泰克斯药物股份有限公司 旋转酶和拓扑异构酶抑制剂的磷酸酯
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
RU2744460C2 (ru) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
MX380578B (es) * 2014-10-03 2025-03-12 Ucb Biopharma Sprl Derivados de imidazol pentaciclicos fusionados.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013186229A1 (en) * 2012-06-11 2013-12-19 Ucb Pharma S.A. Tnf -alpha modulating benzimidazoles
WO2014009295A1 (en) * 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity
WO2014009296A1 (en) * 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyrazine derivatives as modulators of tnf activity

Also Published As

Publication number Publication date
CA2962826C (en) 2023-08-08
US20210155637A1 (en) 2021-05-27
MY181019A (en) 2020-12-16
ZA201701946B (en) 2018-07-25
KR102442235B1 (ko) 2022-09-08
UY36341A (es) 2016-04-29
EA201790734A1 (ru) 2017-09-29
AU2015326798B2 (en) 2020-01-02
TN2017000083A1 (en) 2018-07-04
SI3201196T1 (sl) 2021-12-31
PH12017500414A1 (en) 2017-07-17
WO2016050975A1 (en) 2016-04-07
EA032839B1 (ru) 2019-07-31
MA40770A (fr) 2021-03-24
JP6629847B2 (ja) 2020-01-15
MA40770B1 (fr) 2021-11-30
BR112017006669B1 (pt) 2023-04-18
CL2017000787A1 (es) 2017-11-24
US10906919B2 (en) 2021-02-02
CO2017003331A2 (es) 2017-09-29
EP3201196B1 (en) 2021-07-28
PH12017500414B1 (en) 2021-09-10
TW201629067A (zh) 2016-08-16
CA2962826A1 (en) 2016-04-07
ECSP17027306A (es) 2017-05-31
IL251147A0 (en) 2017-04-30
MX2017004201A (es) 2017-05-30
KR20170068503A (ko) 2017-06-19
PE20170693A1 (es) 2017-06-13
AU2015326798A1 (en) 2017-04-06
RS62423B1 (sr) 2021-10-29
HRP20211605T1 (hr) 2022-01-21
US20190367535A1 (en) 2019-12-05
IL251147B (en) 2020-05-31
UA120764C2 (uk) 2020-02-10
US11912721B2 (en) 2024-02-27
CN107108672A (zh) 2017-08-29
AP2017009809A0 (en) 2017-03-31
PL3201196T3 (pl) 2022-01-03
NZ730256A (en) 2021-05-28
DK3201196T3 (da) 2021-09-06
BR112017006669A2 (pt) 2017-12-26
GT201700044A (es) 2019-09-09
ES2885432T3 (es) 2021-12-13
TWI719949B (zh) 2021-03-01
US20170305932A1 (en) 2017-10-26
US10202405B2 (en) 2019-02-12
EP3201196A1 (en) 2017-08-09
SG11201701796XA (en) 2017-04-27
MX380578B (es) 2025-03-12
JP2017531648A (ja) 2017-10-26
CR20170167A (es) 2017-08-10
HUE056133T2 (hu) 2022-01-28
LT3201196T (lt) 2021-09-27

Similar Documents

Publication Publication Date Title
CN107108672B (zh) 稠合的五环咪唑衍生物
CN109219609B (zh) 作为tnf活性调节剂的稠合六环咪唑衍生物
CN104619709B (zh) 作为tnf活性调节剂的咪唑并吡啶衍生物
CN105814048B (zh) 作为tnf活性调节剂的稠合三环苯并咪唑衍生物
JP6445560B2 (ja) Ｔｎｆ活性のモジュレーターとしての縮合三環式イミダゾール誘導体
CN107873031B (zh) 作为tnf活性调节剂的苯并噁嗪酮衍生物及其类似物
CN104470924B (zh) 作为tnf活性调节剂的咪唑并吡嗪衍生物
CN110167935B (zh) 作为αV整合素抑制剂的3-经取代的丙酸
CN109195969B (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
CN109195968B (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
CN104470925A (zh) 作为激酶抑制剂的咪唑并三嗪甲腈
TW201630907A (zh) ＴＧＦβＲ拮抗劑
CN110461842A (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
CN107709322A (zh) 作为抗癌剂的三环化合物
CN107690434B (zh) 作为tnf活性调节剂的稠合三环咪唑并吡嗪衍生物
CN114929345A (zh) 作为toll受体抑制剂的经取代的吡唑化合物
CN109219608B (zh) 作为tnf活性调节剂的稠合五环咪唑衍生物
HK1240916B (en) Fused pentacyclic imidazole derivatives
NZ730256B2 (en) Fused pentacyclic imidazole derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant